All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
Combination of everolimus and LDAC was not effective in elderly AML patients – a phase Ib study
In Acute Myeloid Leukemia (AML), aberrant mammalian Target of Rapamycin (mTOR) signaling occurs in approximately 50–80% of patients and it is associated with poor outcomes and therapy resistance.1
In a Letter to the Editor of Leukemia & Lymphoma, Ing S. Tiong from the Alfred Hospital, Melbourne, Australia, et al. reported results from their phase Ib dose-escalation study (NCT00636922), which aimed to determine the efficacy and tolerability of everolimus (inhibitor of Mammalian Target of Rapamycin Complex 1 [mTORC1]) in combination with Low Dose cytarabine (LDAC) in elderly patients with AML who are unfit for intensive chemotherapy.2
In total, 24 AML patients (median age = 74 years) were enrolled in this study between March 2008–July 2009. Patients were administered subcutaneous LDAC 20mg twice daily for 10 days every 28–42 day for four cycles and continuous oral everolimus at one of three dose levels including 2.5 mg (n = 8), 5mg (n = 8) or 10 mg (n = 8) for up to 3 months.
The key results of the study were:
- Dose Limiting Toxicities (DLTs) were observed in patients in the 2.5 mg (leukocytosis flare, n = 1), 5 mg (heart failure, n = 1) and in the 10 mg (cough [n = 1], mouth ulcers [n = 1] and sepsis [n = 2]) cohort
- Grade 4 adverse events occurred including thrombocytopenia (58%) and neutropenia (67%)
- Overall Response Rate (ORR); 25% (6/24)
- Median Overall Survival (OS)
- All patients; 6.0 months
- In patients administered 2.5, 5.0 and 10 mg everolimus; 7.1 vs 6.3 vs 4.6 months
- Responders and non-responders; 18.9 vs 5.5 months, P = 0.041
- Poor risk and standard-risk patients; 5.7 vs 8.0 months, P = 0.028
In summary, the findings of the study did not “reveal an efficacy signal for the combination of LDAC with the mTORC1 inhibitor everolimus”. Additionally, the “combination might increase toxicity, with DLTs encountered with 10 mg everolimus in combination with LDAC”.
The authors concluded by suggesting that future studies should investigate the combination of mTOR inhibitors with other novel agents in the therapy for AML in order to answer biologically targeted questions.
References